Scilex Holding (SCLX) Asset Writedowns and Impairment (2024 - 2026)
Scilex Holding (SCLX) posted quarterly Asset Writedowns and Impairment of $324000.0 for Q1 2026, up 112.83% quarter-over-quarter from -$2.5 million in Q4 2024.
Scilex Holding (SCLX) Asset Writedowns and Impairment (2024 - 2026) Analysis & Trends
Scilex Holding's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $324000.0 for Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $324000.0; the TTM figure through Mar 2026 stood at -$2.2 million (down 60.15% YoY), while the FY2025 annual figure was $73.4 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $324000.0, up from -$2.5 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $1.4 million in Q1 2024, with the low at -$2.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 324,000.00 |
| Mar 31, 2026 | 324,000.00 |
| Dec 31, 2024 | -2.53 Mn |
| Dec 31, 2024 | -2.53 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.38 Mn |